For the first time in the federal NEC baby formula litigation, a case against Mead Johnson is headed to trial. The case involves the death of a premature infant whose mother alleges that Mead Johnson’s Enfamil Premature formula contributed to his development of necrotizing enterocolitis, commonly known as NEC.
The trial represents an important moment in litigation that has been developing for years. Hundreds of lawsuits involving Mead Johnson and Abbott Laboratories have been centralized in multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois.
For families of premature infants who developed NEC after receiving Enfamil, Similac, or other cow’s milk-based preterm infant products, Inman is worth watching. It will give a federal jury an opportunity to consider evidence and arguments that have been at the center of these cases: what manufacturers knew about the risk of NEC, what information physicians received, whether additional warnings could have changed feeding decisions, and whether a particular child’s exposure to formula contributed to the disease.
What Is the Inman NEC Baby Formula Lawsuit About?
Alexis Inman filed the lawsuit following the death of her son Daniel, who was born prematurely in 2020 at 29 weeks gestation and weighed less than two pounds. According to court records, Daniel initially received his mother’s breast milk before later being fed Enfamil Premature, a cow’s milk-based formula manufactured by Mead Johnson. He subsequently developed NEC and died.
Inman alleges that Mead Johnson failed to adequately warn about the NEC risks associated with its product. Mead Johnson disputes those allegations. The case is one of several selected to serve as bellwethers in the federal NEC litigation.
Bellwether cases are intended to provide both sides with information about how juries may evaluate recurring evidence, expert testimony, and legal arguments. A verdict in Inman would not determine the outcome of other NEC lawsuits, but what happens at trial could influence how plaintiffs and defendants evaluate cases going forward.
Why Reaching a Federal Jury Is Significant
The road to this first Mead Johnson federal trial has not been straightforward.
Several earlier bellwether cases against Abbott Laboratories ended before a jury could hear them after the court granted summary judgment in Abbott’s favor.
Inman followed a different path.
In May, U.S. District Judge Rebecca R. Pallmeyer allowed key claims against Mead Johnson to move forward. Among other issues, the court concluded that a jury could consider whether additional information about the relative risks of formula and breast milk might have affected decisions regarding Daniel’s nutrition.
Mead Johnson later made another attempt to prevent the trial from proceeding, relying in part on the U.S. Supreme Court’s June 2026 ruling in Monsanto Co. v. Durnell. The company argued that the Supreme Court’s reasoning concerning federal preemption should affect Inman’s claims because infant formula is regulated by the U.S. Food and Drug Administration.
Judge Pallmeyer disagreed, distinguishing the federal laws and regulatory schemes involved. That decision cleared another major hurdle and allowed Inman to proceed toward trial.
What Are Families Alleging in NEC Baby Formula Lawsuits?
NEC is a serious gastrointestinal disease that can affect premature and very-low-birth-weight infants. It can cause intestinal tissue to become inflamed and die, sometimes requiring emergency surgery. Severe cases can be fatal.
The nationwide NEC preterm infant formula litigation focuses on allegations involving cow’s milk-based formula and fortifier products designed for premature infants, including certain Enfamil products manufactured by Mead Johnson and Similac products manufactured by Abbott.
Plaintiffs generally allege that the companies failed to adequately warn healthcare providers and families about evidence concerning an increased risk of NEC among premature infants fed cow’s milk-based products compared with an exclusively human-milk diet.
Abbott and Mead Johnson deny liability and have challenged the lawsuits on issues including causation, warnings, product design and federal regulation.
Those disputes are important. An association between a type of feeding and NEC risk doesn’t by itself establish that formula caused NEC in an individual infant or that a manufacturer is legally responsible. Each lawsuit ultimately depends on the evidence surrounding that child, including medical history, gestational age, feeding records, product exposure, and the circumstances surrounding the NEC diagnosis.
NEC Baby Formula Verdicts Have Produced Different Results
The Inman trial also arrives against a complicated backdrop of NEC cases tried in state courts. Some juries have returned substantial verdicts for families. In April 2026, an Illinois jury awarded $70 million to four mothers who alleged that their premature babies developed NEC after receiving Abbott’s Similac Special Care 24 formula.
Other cases have ended differently. Manufacturers have won defense verdicts, and appeals have altered some earlier results.
In June, an Illinois appellate court ordered a new trial in a case that had resulted in a $60 million verdict against Mead Johnson. Meanwhile, a Missouri appellate court declined to reconsider its decision upholding a $495 million verdict against Abbott.
I recently wrote about those two appellate decisions and why they illustrate how much remains unsettled in the NEC baby formula litigation. The varying outcomes are also a reminder that no single NEC case can predict what will happen in every other lawsuit.
What Could the Mead Johnson Bellwether Trial Tell Us?
For lawyers and families following these cases, one of the most important aspects of Inman is that a federal jury will have the opportunity to evaluate evidence that has been debated throughout the litigation.
Jurors may hear competing testimony about the causes and risk factors for NEC, the scientific evidence surrounding feeding practices for premature infants, Mead Johnson’s warnings, and whether different information could have changed the decisions made in Daniel’s care.
How jurors respond to that evidence could give both sides a better understanding of the strengths and weaknesses of similar claims. But it’s important not to overstate what a single bellwether means.
Even a plaintiff or defense verdict wouldn’t automatically resolve the hundreds of other NEC baby formula lawsuits. Bellwether trials are informative rather than binding on families whose cases are not before that jury.
The more meaningful picture will emerge over time as additional cases move through trials, appeals and potentially settlement discussions.
Another Major Federal NEC Trial Is Scheduled for October
The next major federal trial currently scheduled involves Abbott Laboratories. That case is expected to begin October 19, 2026, and my law partner, C. Andrew Childers, is preparing to help lead the trial alongside Plaintiff MDL Co-Lead Timothy Becker of Johnson // Becker.
That direct involvement gives our firm a particularly close view of how the federal litigation is developing.
Childers, Schlueter & Smith represents families nationwide in NEC baby formula lawsuits involving premature infants who developed NEC after receiving cow’s milk-based formula or fortifier products.
As these federal trials begin, families should remember that the outcome of a bellwether doesn’t determine whether they have a potential claim. An NEC lawsuit requires an individual review of the child’s medical and feeding history, the products involved, and the applicable law.
Parents whose premature infant developed NEC after receiving Enfamil, Similac, or another cow’s milk-based preterm infant formula or fortifier can learn more about when it may be appropriate to contact an NEC baby formula lawyer. Families with questions about a potential NEC baby formula lawsuit can also contact Childers, Schlueter & Smith online, use our live chat now, or call 1-800-641-0098 to speak with our legal team.
